Advaxis to hold End-of-Phase 2 meeting with FDA

|About: Advaxis Inc. (ADXS)|By:, SA News Editor

The FDA agrees to an End-of-Phase 2 meeting with Advaxis (ADXS) to discuss the clinical results of its lead cancer immunotherapy candidate ADXS-HPV. The purpose of the meeting is to assess what needs to be done to move into a Phase 3 trial.

ADXS-HPV is being studied for the treatment of HPV-related cancers. The FDA designated it an Orphan Drug for Stage II-IV invasive cervical cancer.